Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis.
Agis H, Weltermann A, Fonatsch C, Haas O, Mitterbauer G, Müllauer L, Schreiber S, Schwarzinger I, Juretzka W, Valent P, Jäger U, Lechner K, Geissler K. Agis H, et al. Among authors: fonatsch c. Ann Hematol. 2002 Feb;81(2):90-5. doi: 10.1007/s00277-001-0412-9. Epub 2002 Jan 23. Ann Hematol. 2002. PMID: 11907789
A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5).
Sperr WR, Piribauer M, Wimazal F, Fonatsch C, Thalhammer-Scherrer R, Schwarzinger I, Geissler K, Knöbl P, Jäger U, Lechner K, Valent P. Sperr WR, et al. Among authors: fonatsch c. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3965-71. doi: 10.1158/1078-0432.CCR-04-0185. Clin Cancer Res. 2004. PMID: 15217926
Highly refractory acute myeloid leukemia.
Füreder W, Filipits M, Sperr WR, Kainz B, Jäger U, Fonatsch C, Schwarzinger I, Haas OA, Pirker R, Lechner K. Füreder W, et al. Among authors: fonatsch c. Wien Klin Wochenschr. 2004 Aug 31;116(15-16):561-4. doi: 10.1007/BF03217710. Wien Klin Wochenschr. 2004. PMID: 15471184 Clinical Trial.
Excellent disease eradication by myeloablative therapy and stem-cell transplantation in patients with acute myelogenous leukemia.
Greinix HT, Loidolt H, Rabitsch W, Schulenburg A, Keil F, Mitterbauer M, Laczika K, Lechner K, Dieckmann K, Fischer G, Jäger U, Rosenmayr A, Knöbl P, Schwarzinger I, Höcker P, Mannhalter C, Hinterberger W, Haas OA, Fonatsch C, Kalhs P. Greinix HT, et al. Among authors: fonatsch c. Ann Hematol. 2000 Apr;79(4):206-13. doi: 10.1007/s002770050580. Ann Hematol. 2000. PMID: 10834508 Clinical Trial.
Low curative potential of bone marrow transplantation for highly aggressive acute myelogenous leukemia with inversioin inv (3)(q21q26) or homologous translocation t(3;3) (q21;q26).
Reiter E, Greinix H, Rabitsch W, Keil F, Schwarzinger I, Jaeger U, Lechner K, Worel N, Streubel B, Fonatsch C, Mitterbauer G, Kalhs P. Reiter E, et al. Among authors: fonatsch c. Ann Hematol. 2000 Jul;79(7):374-7. doi: 10.1007/s002770000158. Ann Hematol. 2000. PMID: 10965785
255 results